Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SatiPurple
- Development stage
- Unknown
- Lead developer
- Delivra
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Inhalation
01
Overview
**SatiPurple** is a high-CBD medical cannabis product from the Satipharm brand, color-coded to indicate its position at the high CBD end of a THC-CBD continuum ranging from SatiWhite (high THC) to SatiPurple (high CBD). Developed as part of a standardized product line for medical use, it is indoor-grown cannabis intended to assist consumers in making informed choices for health and wellness applications, supplied through partnerships like Shoppers Drug Mart in Canada.[3][4][8]
- Brand names
- SatiPurple
Beyond the preview
Go deeper on SatiPurple.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SatiPurple.